
Jeremie Calais
@calaisjeremie
Nuclear medicine and theranostics at UCLA
@UCLA @UCLAJCCC @UCLATheranostic
@UCLAnewsroom @UCLAHealth
#PETCT #nuclearmedicine #theranostics
ID: 1317210197765484546
16-10-2020 21:06:18
662 Tweet
1,1K Followers
203 Following




Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…


... how common is PSMA-negative significant prostate cancer? In the proPSMA study it was 3.3% Hot of the press in JNM: jnm.snmjournals.org/content/early/… Wonderful work from David Chen and team ProsTIC including James Buteau Declan Murphy


Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

Lot of content, Great Presentations and discussions during these 2 days ! Thank you all !! Jeremie Calais Thomas Hope PCF Science UCLA UC San Francisco UroToday.com Johannes Czernin



¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q #NuclearMedicine #PETscan Ashwin Singh Parihar, MBBS, MD





Stunning research from Edmond Kwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative




